Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Rhinosinusitis With Nasal Polyposis Clear all
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

NCT06914908
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Lunsekimig, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
La Jolla, California • Roseville, California • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 21, 2026, 9:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP

NCT05672030
View directory record Official record
Conditions
Nasal Polyps, Aspirin-exacerbated Respiratory Disease
Interventions
Non-Interventional
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia

NCT02217332
View directory record Official record
Conditions
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Interventions
dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Boca Raton, Florida • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Jul 21, 2026, 9:24 AM EDT
Active, not recruiting No phase listed Observational

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

NCT04959448
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyposis
Interventions
DUPIXENT®
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
48
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

NCT05281523
View directory record Official record
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
14
States / cities
Tucson, Arizona • Roseville, California • New Haven, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jul 21, 2026, 9:24 AM EDT
Recruiting Not applicable Interventional

Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

NCT07290140
View directory record Official record
Conditions
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Interventions
Airiver ESSpand DCB, ESS
Combination Product · Procedure
Lead sponsor
Airiver Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps

NCT01623323
View directory record Official record
Conditions
Chronic Sinusitis With or Without Nasal Polyps
Interventions
Fluticasone Propionate
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years and older
Enrollment
705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Phoenix, Arizona • Colorado Springs, Colorado • Largo, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Jul 21, 2026, 9:24 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Chronic Rhinosinusitis With or Without Nasal Polyps Steroid Study

NCT00841802
View directory record Official record
Conditions
Chronic Sinusitis, Rhinosinusitis, Nasal Polyps
Interventions
Prednisone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps

NCT01732536
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyps
Interventions
S8 Sinus Implant, Sham procedure, Mometasone furoate nasal spray
Drug · Procedure
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Atherton, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 21, 2026, 9:24 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Dupixent Study for Alternate Administration

NCT06750471
View directory record Official record
Conditions
Nasal Polyps, Sinusitis, Chronic Disease
Interventions
Dupilumab
Biological
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Phase 2 Interventional Results available

Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis

NCT01066104
View directory record Official record
Conditions
Chronic Rhinosinusitis, Nasal Polyps
Interventions
Xolair placebo, Xolair (omalizumab)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

NCT03781804
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
OPN-375
Drug
Lead sponsor
Optinose US Inc.
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
46
States / cities
Gilbert, Arizona • Bakersfield, California • Folsom, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Jul 21, 2026, 9:24 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Adjunctive Treatment for Chronic Rhinosinusitis With Nasal Polyposis

NCT03607175
View directory record Official record
Conditions
Chronic Rhinosinusitis, Nasal Polyps
Interventions
Triamcinolone-impregnated CMC foam, Propel Stent
Drug · Device
Lead sponsor
Marina Boruk
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 21, 2026, 9:24 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Laser Assisted Treatment of Chronic Sinusitis With and Without Light Activated Agents

NCT00948519
View directory record Official record
Conditions
Rhinosinusitis
Interventions
Laser + ICG, Laser only
Device
Lead sponsor
New York Head & Neck Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Early Phase 1 Interventional

Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis

NCT04583501
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Nasal Polyps
Interventions
Omalizumab
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Dupilumab in CRSsNP

NCT04678856
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
Interventions
Dupilumab SAR231893, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Roseville, California • Stockton, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 21, 2026, 9:24 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

NCT04157335
View directory record Official record
Conditions
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Interventions
Benralizumab 30 mg, Matched placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Phase 4 Interventional Results available

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

NCT04998604
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Asthma
Interventions
Dupilumab, Omalizumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jul 21, 2026, 9:24 AM EDT
Withdrawn Phase 4 Interventional

Early-onset Dupilumab Effects in CRSwNP

NCT06188871
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Dupilumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Jul 21, 2026, 9:24 AM EDT
Recruiting No phase listed Observational

Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.

NCT06892704
View directory record Official record
Conditions
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Smell Loss
Interventions
Dupilumab - Standard Dose
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 9:24 AM EDT
Withdrawn No phase listed Observational

Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

NCT03369574
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis), Asthma, Nasal Polyps
Interventions
Reslizumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

NCT04851964
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid
Biological · Other · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Bakersfield, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Phase 2 Interventional

A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps

NCT06454240
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
lunsekimig, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
La Jolla, California • Roseville, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 21, 2026, 9:24 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps

NCT03280537
View directory record Official record
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Tucson, Arizona • Rancho Cordova, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Jul 21, 2026, 9:24 AM EDT